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Currently emerging big data techniques are reshaping medical science into a data science. Medical
claims data allow assessing an entire nations health state in a quantitative way, in particular with
regard to the occurrences and consequences of chronic and pandemic diseases like diabetes. We
develop a quantitative, statistical approach to test for associations between the incidence of type 1
or type 2 diabetes and any possible other disease as provided by the ICD10 diagnosis codes using a
complete set of Austrian inpatient data. With a new co-occurrence analysis the relative risks for each
possible comorbid disease are studied as a function of patient age and gender, a temporal analysis
investigates whether the onset of diabetes typically precedes or follows the onset of the other disease.
The samples is always of maximal size, i.e. contains all patients with that comorbidity within the
country. The present study is an equivalent of almost 40,000 studies, all with maximum (complete)
patient number available in the country. Out of more than thousand possible associations, 123
comorbid diseases for type 1 or type 2 diabetes are identified at high significance levels. Well known
diabetic comorbidities are recovered, such as retinopathies, hypertension, overweight, chronic kidney
diseases, etc. This validates the method. Additionally, a number of comorbidities are identified
which have only been recognized to a lesser extent, for example epilepsy, sepsis, or several mental
disorders. The temporal evolution, age, and gender-dependence of these comorbidities are discussed.
The new statistical-network methodology developed here can be readily applied to other chronic
diseases.
PACS numbers:
BACKGROUND
The emerging availability of big data transforms med-
ical sciences into a data science. Nation-wide collections
of physician and hospital claims data allow exploring the
health state of an entire countrys population with un-
precedented precision and scale [1]. The enormous po-
tential of such claims data has been shown by developing
or improving data-driven comorbidity indices to predict
mortality rates [2] , or by studying healthcare utiliza-
tion and outcome measures of specific patient cohorts
[3]. In this work we show how to use a nation-wide claims
dataset to generate and cross-validate hypothesis on each
possible comorbidity association for type 1 (DM1) and 2
diabetes (DM2), and how they depend on patient age,
gender, and temporal order of the disorders onsets.
Diabetes is a global pandemic disease. The world-wide
number of adult diabetes patients doubled over the last
three decades to approximately 350 million as of 2010,
and is expected to double again until 2030 as a result of
population ageing and a shift to western lifestyle patterns
in developing countries [4]. Diabetes comprises a het-
erogeneous group of disorders with the most prominent
types being DM1 and DM2. These disorders have differ-
ent pathophysiologies and phenotypes; the exact under-
lying mechanisms, their interplay finally leading to man-
ifestation, progressions of the diseases, and their com-
plications are still unclear. Diabetes is associated with
a large number of comorbid diseases, including but not
limited to vascular complications [5], renal failures [5],
neuropathy [5], heart diseases [6, 7], cognitive disorders
[8, 9], retinopathy [10], and hypertension [11]. Each of
these comorbidities opens up a unique direction of re-
search. Following the methodological approach devel-
oped in this work, thousands of such associations can be
investigated in parallel. Besides studying the individual
diabetic comorbidities, and how they depend on patient
age and gender, this allows to compare the strength of
these associations among each other and rank them ac-
cording to their incidences. The methodology developed
here can be readily applied to obtain complete comorbid-
ity profiles for other disorders than diabetes.
METHODS
Data. A database of the Main Association of Austrian
Social Security Institutions containing pseudonymised
claims data of all persons receiving out- and inpatient
care in Austria between January 1st, 2006 and Decem-
2ber 31st, 2007 is used [12]. The data gives a comprehen-
sive, nation-wide picture of the medical condition of most
of the approximately 8.3 million Austrians. The patient
collective was formed by extracting all persons receiving
inpatient care in 2006 or 2007. We identified patients
being diagnosed with DM1 or DM2 (ICD10 codes E10
and E11). Patients who died in 2006 or 2007 were re-
moved. In this way 16,667 DM1 patients (8,355 males
and 8,312 females) and 105,904 with DM2 (50,596 males
and 55,308 females) were selected. The total sample of in-
patients consists of 1,862,258 patients (1,064,952 females
and 797,306 males). From these patients we know their
year of birth, sex, ATC codes of all their prescriptions,
and the ICD codes of all their diagnoses (main- and side-
diagnoses).
Co-occurrence analysis. For the occurrences of
each diagnosis x (ICD10, three-digit-level) a patient-age-
resolved cross tabulation with the occurrences of DM1
and DM2 is performed. Symptoms, injuries, pregnan-
cies, and external causes and factors of morbidity were
excluded. The patients are grouped according to their
age in five-year intervals. For each diagnosis and age in-
terval a contingency table is built. If each entry in the
table is greater than 10, relative risks RR1(2)(x, t) are
computed, a chi-squared test is performed and p-values
are calculated for rejecting the null hypothesis that co-
occurrence of the diagnoses with DM1 or DM2 is indepen-
dent. The Benjamini-Hochberg procedure [13] is applied
to control for the false discovery rate α. If there are less
than ten co-occurrences or the results are not significant,
the relative risk is set to one.
Gender ratio. The gender ratio GR(x, t) is related
to the quotient of the percentage of female and male dia-
betes patients in age group t who also have diagnoses x,
see supplementary information.
Lead/lag indicator. The lead/lag indicators assess
whether patients with diagnoses di are more likely to be
later in their life diagnosed with another disease x, the
lead indicator Ilead(di, x), or whether it is more likely
that people having diagnoses x will be diagnosed with
diabetes, the lag indicator Ilag(di, x), see supplementary
information.
RESULTS
Figure 1(a) shows the fraction of male and female in-
patients of the entire population as a function of age.
The inpatient fractions are around 20% for children un-
der five, then drop to 10-15% for ages around ten, and
from then on rise to more than 80% for 80 year-old pa-
tients, with an additional peak for females of age around
30, most likely due to child birth. Figure 1(b) shows the
fraction of male and female DM1 inpatients as a func-
tion of age. The distributions are bimodal with one peak
around the typical onset-age of ten for both male and
females, and a second peak for ages 60 (70) for males
(females). Figure 1(c) shows the fractions of inpatients
diagnosed with DM2 as a function of age, with compara-
bly few patients below age thirty, and the bulk of male
(female) patients concentrated around age 60 (70).
Figure 1 shows GR(y, t) for DM1 patients and their
number of diagnoses (d) and received drugs (e), (f) and
(g) show the same for DM2 patients. Up to an age of 60
there is an excess of male patients, for older patients there
is an excess of females. For drugs there is a male excess
only for age up to 60 and for less than 10-20 drugs. For
older age and a larger number of drugs there is an excess
of female patients. Females below age 60 have thus fewer
diagnoses than males, but especially those with a large
number of diagnoses have more prescriptions than males.
After age 60, females outweigh males in both diagnoses
and prescriptions.
Co-occurrence analysis. Each diagnosis where the
null hypothesis of statistical independence with either
DM1 or DM2 can be rejected with a false discovery rate
of α < 0.01 in at least one of the age groups is identified
as a comorbidity. The results are summarized in Figure
2 and Figure 3, with the left columns showing the DM1
relative risk RR1(x, t), the middle columns the DM2 rel-
ative risk RR2(x, t), and the right columns the gender
ratio GR(x, t). The comorbidities are also listed in the
supplement, Table S1, along with relative risks, p-values,
and patient ages for the age group with the smallest p-
values for DM1 and DM2, respectively. In the following
we refer to these values whenever referring to the relative
risks of a diagnosis with a 95% confidence interval (CI).
Lead/lag analysis. To identify lead/lag behavior
Ilead(di, x) and Ilag(di, x) are computed for male and fe-
male DM1 and DM2 patients. A leading or lagging re-
lationship is identified if the null hypothesis that the ob-
served indicator values can be obtained from randomized
surrogate data can be rejected with a p-value of p < 0.05,
see the supplement for details on the randomization pro-
cedure. Table I shows diagnoses which have been identi-
fied as either leading or lagging for male or female DM1
or DM2 patients, as well as their corresponding p-values.
DISCUSSION
Infections and sepsis. Bacterial and viral infections
can be found among the comorbidities (gastroenteritis,
erysipelas, pneumonia, osteomyelitis, hepatitis [14], der-
matophytosis [15], candidiasis). Most infections show an
excess of male patients, exceptions are gastroenteritis and
candidiasis which are dominated by female patients. It
has been disputed whether diabetes increases susceptibil-
ity for sepsis or is potective [16]. However diabetes is a
common comorbity (incidence of 23%) in septic patients
[17]. We find an excess of sepsis comorbidity which is
strongest in male DM1 patients at the age around 50,
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FIG. 1: The fraction of inpatients in the entire population as a function of age is similar in males and females, except for an
excess of females at the age around 30, most likely related to giving birth (a). After a peak in early childhood, the fraction
of inpatients increases to levels of above 80% in older age. The bulk of male (female) (b) DM1 and (c) DM2 patients is aged
around 60 (70), for DM1 patients there is a second peak around age 10. The gender ratio GR(y, t) is shown for DM1 (d,e) and
DM2 (f,g) patients and the number of their diagnoses (d,f) and their prescriptions (e,g). For patients younger than 60, with a
comparably high number of comorbidities, female patients have less diagnoses but take more drugs than males.
with higher relative risks for DM1 (12, CI 8.2-18) than
DM2 (2.7, CI 2.4-2.9).
Neoplasms. At present it is unclear if new onset di-
abetes is a specific marker of pancreatic cancer or if dia-
betic patients in general are at increased risk of pancre-
atic cancer with a pooled RR of approximately 2 com-
pared to non-diabetics in a meta-analysis [18] with at
least 1 year diabetes duration prior to diagnosis of pan-
creatic cancer [19]. In our dataset there is an excess
of male patients and higher relative risks for DM1 pa-
tients (8.6, CI 5.6-13) than DM2 patients (2.5, CI 2.1-
2.8), potentially outlining greater impact of chronic hy-
perglycemia than of overweight-related parameters of the
metabolic syndrome. It is identified as lagging behind
the onset of DM2 in female patients, which might sug-
gest that DM2 increases the risk of this cancer at least
in females.
Anaemia. Diabetes is a known risk factor for anaemia
[20]. Iron-deficiency and anaemia in chronic diseases
show higher relative risks for DM1 (3.7, CI 3.0-4.6, and
6.3, CI 4.9-8.1, respectively) than DM2 (2.7, CI 2.4-2.9,
and 2.8, CI 2.5-3.2) patients. There is an excess of female
patients in the age range 20-40, thus being related to the
reproductive phase.
Endocrine and metabolic disorders. There are
pronounced gender differences observable in endocrine
and metabolic comorbidities [5]. While patients with
thyroiditis (mostly DM1), hypothyroidism, thyrotoxico-
sis, and obesity are predominantly female, disorders of
the liporoteine, purine, and pyrimidine metabolism tend
to be found in males. It is known that diabetic patients
feature a 2-3 fold higher increased risk of disorders of the
thyroid gland particularly those with autoimmune dia-
betes and that this association is strongly influenced by
gender [21]. For volume depletion and disorders of fluid,
electrolyte and acid-base balance there appears to be an
age switch, from an excess of male patients for younger
ages to females in older age.
Mental and behavioral disorders. Nicotine de-
pendence and alcohol related disorders are comorbidi-
ties with excess-risks peaking at ages 30-45, dominated
by male patients. For males the onset of DM2 lags be-
hind the use of alcohol; alcoholic liver disease is also a
lagging, male-dominated comorbidity. The relationship
between alcohol consumption and DM2 has been shown
to be dosage dependent. While moderate alcohol con-
sumption was protective, dosages of more than 60g/day
increased diabetes risk [22].
Depressions are dominated by female patients [8]. In-
terestingly, the onset of DM1 leads before depressive
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A09: Infectious gastroenteritis ...
A41: Other sepsis
A46: Erysipelas
B17: Other acute viral hepatitis
B18: Chronic viral hepatitis
B35: Dermatophytosis
B37: Candidiasis
B99: Other and unspecified infec...
C25: Malignant neoplasm of pancr...
D50: Iron deficiency anemia
D63: Anemia in chronic diseases ...
D64: Other anemias
D69: Purpura and other hemorrhag...
E03: Other hypothyroidism
E05: Thyrotoxicosis [hyperthyroi...
E06: Thyroiditis
E16: Other disorders of pancreat...
E21: Hyperparathyroidism and oth...
E66: Overweight and obesity
E78: Disorders of lipoprotein me...
E79: Disorders of purine and pyr...
E86: Volume depletion
E87: Other disorders of fluid, e...
E88: Other and unspecified metab...
F01: Vascular dementia
F03: Unspecified dementia
F07: Personality & behavrl disor...
F10: Alcohol related disorders
F17: Nicotine dependence
F20: Schizophrenia
F25: Schizoaffective disorders
F32: Major depressive disorder, ...
F33: Major depressive disorder, ...
F79: Unspecified intellectual di...
G20: Parkinson’s disease
G30: Alzheimer’s disease
G40: Epilepsy and recurrent seiz...
G45: Transient cerebral ischemic...
G46: Vascular syndromes of brain...
G47: Sleep disorders
G62: Other and unspecified polyn...
G63: Polyneuropathy in diseases ...
G81: Hemiplegia and hemiparesis
H21: Other disorders of iris and...
H25: Age−related cataract
H26: Other cataract
H33: Retinal detachments and bre...
H35: Other retinal disorders
H36: Retinal disorders in diseas...
H40: Glaucoma
H43: Disorders of vitreous body
H54: Blindness and low vision
I10: Essential (primary) hyperte...
I11: Hypertensive heart disease
I12: Hypertensive chronic kidney...
I13: Hypertensive heart and chro...
I15: Secondary hypertension
I20: Angina pectoris
I21: STEMI & NSTEMI mocard infrc
I24: Other acute ischemic heart ...
I25: Chronic ischemic heart dise...
I27: Other pulmonary heart disea...
males females
FIG. 2: Relative risks for DM1 (left column) and DM2 (middle column) patients, and gender ratios (right column) for core
comorbidities using a false discovery rate of α < 0.01 and an ICD code from the range A01-I27. Color encodes the values of
the risks and gender ratios.
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I34: Nonrheumatic mitral valve d...
I35: Nonrheumatic aortic valve d...
I42: Cardiomyopathy
I44: Atrioventricular and left b...
I45: Other conduction disorders
I47: Paroxysmal tachycardia
I48: Atrial fibrillation and flu...
I49: Other cardiac arrhythmias
I50: Heart failure
I51: Complications and ill−defin...
I63: Cerebral infarction
I64: Stroke, not specified as he...
I65: Occls and stenosis of prece...
I67: Other cerebrovascular disea...
I69: Sequelae of cerebrovascular...
I70: Atherosclerosis
I73: Other peripheral vascular d...
I74: Arterial embolism and throm...
I77: Other disorders of arteries...
I79: Disord of art, arterioles a...
I85: Esophageal varices
I87: Other disorders of veins
J15: Bacterial pneumonia, not el...
J18: Pneumonia, unspecified orga...
J20: Acute bronchitis
J22: Unspecified acute lower res...
J44: Other chronic obstructive p...
J81: Pulmonary edema
J90: Pleural effusion, not elsew...
J96: Respiratory failure, not el...
K29: Gastritis and duodenitis
K40: Inguinal hernia
K52: Other and unsp noninfective...
K70: Alcoholic liver disease
K71: Toxic liver disease
K74: Fibrosis and cirrhosis of l...
K76: Other diseases of liver
K80: Cholelithiasis
K83: Other diseases of biliary t...
K85: Acute pancreatitis
K86: Other diseases of pancreas
K90: Intestinal malabsorption
L03: Cellulitis and acute lympha...
L30: Other and unspecified derma...
L89: Pressure ulcer
L97: Non−pressure chronic ulcer ...
L98: Oth disorders of skin, subc...
M20: Acquired deformities of fin...
M23: Internal derangement of kne...
M47: Spondylosis
M54: Dorsalgia
M86: Osteomyelitis
N04: Nephrotic syndrome
N08: Glomerular disorders in dis...
N17: Acute kidney failure
N18: Chronic kidney disease (CKD...
N19: Unspecified kidney failure
N25: Disorders resulting from im...
N28: Oth disorders of kidney and...
N39: Other disorders of urinary ...
N47: Disorders of prepuce
males females
FIG. 3: Relative risks for DM1 (left column) and DM2 (middle column) patients, and gender ratios (right column) for core
comorbidities using a false discovery rate of α < 0.01 and an ICD code from the range I34-N99. Color encodes the values of
the risks and gender ratios.
6TABLE I: Diagnoses are shown which have been identified in the lead/lag analysis. For each diagnoses the order (if diabetes
leads or lags), gender (’F’ for females, ’M’ for males) and diabetes type (I or II) where the relationship was detected are listed.
ICD (diagnosis) diabetes type gender
Diabetes leads (comes before the other disease)
C25 Malignant neoplasm of pancreas II F
D63 Anaemia in chronic disease II F
D69 Purpura and other haemorrhagic conditions II F
E86 Volume depletion II F
F01 Vascular dementia II M + F
F07 Personality and behavioral disorders due to known physiological condition II F
F32 Depressive episode I M
G20 Parkinsons disease II M
G47 Sleep disorders II F
I25 Chronic ischaemic heart disease II M
I48 Atrial fibrillation and flutter II M + F
I50 Heart failure II F
J44 Other chronic pulmonary diseases II F
J90 Pleural effusion, not elsewhere classified II F
K52 Other and unspecified noninfective gastroenteritis and colitis II M
K83 Other diseases of intestine II M
L89 Decubitus ulcer II M + F
L97 Ulcer of lower limb n. e. c. II F
N18 Chronic renal failure II M + F
Diabetes lags (comes after the other disease)
F10 Use of alcohol II M
F20 Schizophrenia II F
F25 Schizoaffective disorder II F
I20 Angina pectoris II F
I34 Nonrheumatic mitral valve disorders II M
I85 Esophageal varices II M
K70 Alcoholic liver disease II M
K86 Other diseases of pancreas II M
K90 Intestinal malabsorption I F
M20 Acquired deformities of fingers and toes II F
episodes for male patients, while the onset of DM2 lags
behind schizoaffective disorders and schizophrenia for fe-
males. This is consistent with findings in the literature,
for example symptoms of depression and anxiety have
been shown to be risk factors for the onset of DM2 in-
dependent of established risk factors for diabetes in a
prospective cohort study, while for DM1 no such rela-
tion was identified [9]. Therefore DM1 patients may be-
come depressed due to complications and the burden of
the disease, while for schizoaffective disorders in DM2
patients there may be a similar pathogenetic mecha-
nism or medication-associated increased risk with gender-
differences in the strength of these associations. Depres-
sive and schizoaffective disorders tend to show higher rel-
ative risks for DM2 than DM1 patients.
Diseases of the nervous system. Vascular demen-
tia and Alzheimer are classified as being lead by diabetes
[23]. Both show an excess of female patients. The rela-
tionship between Parkinson’s disease (PD) and diabetes
is disputed. There were two large prospective studies
finding an increased risk for PD associated with diabetes,
one study finding no association, and one study reporting
lower risk of diabetes [24]. Here PD is comorbid with an
excess of male patients, it was detected as being lead by
DM2 for males. There is a known association between
epilepsy and DM1, especially in youth [25]. For ages be-
low 25 we find an excess of female patients which switches
to an excess of males in later years. The relative risk is
also significant for DM2 (4.6, CI 3.1-6.9 for DM1 and 1.6,
CI 1.4-1.7 for DM2). The increased risk in young type 1
diabetics may be linked to ketoacidosis as a 2 fold higher
risk of epilepsy was found in children and adolescents
with metabolic acidosis [26]. A 4fold greater risk of DM1
was also described in young adults with epilepsy [27].
Both metabolic extremes – hypoglycemia and diabetic
ketoacidosis – relate to EEG abnormalities in diabetic
children which may increase risk of epilepsy.
Other comorbidities related to the nervous system
comprise sleep disorders including sleep apnoe (domi-
nated by males), transient cerebral ischemic attacks, and
facial nerve disorders.
Retinopathies. Retinopathies are well known comor-
bidities [10]. Cataracts, retinal detachments, glaucoma,
disorders of the vitreous body, and blindness are iden-
tified here. Relative risks tend to be higher for DM1
patients than for DM2, peaking at ages 45-70.
7Circulatory diseases. Primary hypertension is a co-
morbidity [11] with relative risks of 5.3 (CI 4.8-5.9) for
DM1 and 9.5 (CI 8.8-10) DM2. For ages 20-40 males
dominate, before and after this window female patients
outweigh male ones. Other comorbid diseases of the cir-
culatory system show a consistent excess of male pa-
tients, including ischemic, pulmonary, and other heart
diseases (cardiomyopathy, valvular disorders, tachycar-
dia), as well as cerebrovascular diseases and diseases of
the arteries and veins [5, 7, 28]. For male patients DM2
leads chronic ischemic heart disease, for females DM2
leads heart failure, for both genders it leads atrial fibril-
lation and flutter. On the other hand, DM2 lags behind
the onset of Angina pectoris (females) and nonrheumatic
mitral valve disorders (males). Benign pleural effusion,
representing a symptom of various underlying diseases is
dominated by males and classified as being lead by DM2
for females. In diabetic patients it may be related to left
ventricular dysfunction as described previously [29].
Respiratory diseases. Pneumonia and acute bron-
chitis show increased relative risks for older ages (e.g.
for pneumonia 2.7, CI 2.4-3.0, for DM1, 2.3, CI 2.1-
2.4, for DM2). Diabetes is often identified as indepen-
dent risk factor for lower respiratory tract infections [30].
Other chronic obstructive pulmonary diseases (COPD)
are dominated by males and classified as being lead by
DM2 for females. Individuals with COPD are substan-
tially more likely to have pre-existing DM [31], on the
other hand lung function impairment in COPD is a risk
factor for developing diabetes and insulin resistance [32].
Diseases of the digestive system. Gastritis and
non-infective gastroenteritis are comorbidities with a fe-
male excess, the latter being lead by DM2. For inguinal
hernia there are decreased relative risks irrespective of
patient age (0.37, CI 0.23-0.60, for DM1 and 0.48, CI
0.41-0.56, for DM2). Alcoholic and toxic liver diseases, as
well as cystic fibrosis and pancreatitis are comorbidities
[33], with a male excess. Cholelithiasis is a female dom-
inated comorbidity, a known association which has been
claimed to disappear once one controls for obesity [34],
where there is an increased hepatic secretion of choles-
terol. Intestinal malabsorption (including celiac disease)
shows elevated risks for ages 10-25 for DM1 (10, CI 6.3-
17) with a weak female excess, it also leads the onset of
DM1 for females; there is no significant association with
DM2. In particular, there is a known association between
DM1 and celiac disease [35].
Diseases of the skin. Pressure and non-pressure ul-
cers exhibit higher risks for DM1 (7.2, CI 5.2-9.9, and
7.4, CI 5.8-9.4, respectively) than DM2 patients (2.2, CI
2.0-2.4 and 4.2, CI 3.9-4.6), which may be related to the
diabetic foot ulcer [5]. They are lead by DM2 for both
males and females.
Diseases of the musculoskeletal system. For
spondylosis and dorsalgia elevated risks are dominated
by females. Acquired deformities of fingers and toes,
and internal derangement of knees show reduced risks
for both DM1 and DM2 over the entire age range 15-80,
which cannot be interpreted without further information
on the patients histories and physical exams.
Diseases of the genitourinary system. Chronic
kidney diseases and acute kidney diseases are identified
as comorbidities [5], along with the nephrotic syndrome
and glomerular disorders, each with an excess of male pa-
tients. For males there are increased risks for disorders
of prepuce, while for females there is increased risk for
disorders of the urinary system. Although urologic com-
plications have been recognized since a long time, little is
known about DM as a pathophysiological risk factor for
development of lower urinary tract symptoms (LUTS) in
women [36]. Evidence from epidemiological studies sug-
gests that asymptomatic bacteriuria (ASB) and symp-
tomatic urinary tract infections occur more commonly in
women with DM compared to non-diabetic controls [37].
Prevalence data of urinary incontinence in diabetics are
limited, recent evidence suggests an increased prevalence
of this condition among women with DM2 [38] and large
observational studies have identified urge incontinence as
increased among women with DM [39].
Limitations. Only persons with inpatient stays were
included in the study. To test if this pre-selection intro-
duces a bias in our results, we repeated the study with
a sample of all patients having been prescribed at least
once a drug used in diabetes (ATC code starting with
A10) in 2006 or 2007 at least once. We compare the co-
occurrences of their diseases with the incidences in the
rest of the population. This assumes that DM patients
with no hospital stay in the study period have no diag-
nosis and therefore no comorbidities. Although this is a
highly incorrect assumption, it serves as a conservative
test-assumption, which allows to test if the comorbidities
are simply significant as a consequence of our limited in-
patient sample, where the number of diagnoses per pa-
tients is higher than what would be expected from the
entire population. Results are shown in the supplement
in Figure S1. There only one out of the 123 comorbidi-
ties using the inpatient sample has a p-value greater than
0.05 (M23), all other remain significant (p < 0.05). Sig-
nificance of comorbidity in the inpatient sample is there-
fore highly representative of the entire population. Other
limitations relate to the coding quality of disorders in the
medical claims data, this has been shown to lead to an
under-reporting of comorbidities [40] and may cause false
negatives in our testing procedure.
In summary, in this work we developed a standard-
ized testing procedure to obtain a complete comorbid-
ity profile for DM1 and DM2 using medical claims data.
Out of 39,938 possible comorbidities, we identified 123
with significantly increased or decreased risks as func-
tions of patient age and gender. Comorbidities are in-
vestigated by a lead/lag analysis of the onset of the two
disorders. We recover all the well known diabetic comor-
8bidities (retinopathies, hypertension, overweight, chronic
kidney diseases, etc) and find a number of lesser known
comorbidities such as epilepsy, sepsis, or mental disor-
ders. This shows the validity and power of this method-
ological approach, which may be readily applied to carry
out systematic comorbidity analyses for other chronic dis-
orders.
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SUPPLEMENTARY INFORMATION FOR
’QUANTIFYING AGE- AND GENDER-RELATED
DIABETES COMORBIDITY RISKS USING
NATION-WIDE BIG CLAIMS DATA’
Description of Indicators
Gender ratio. The number of male/female DM1 and
DM2 patients in age group t is denoted Nm/f (d, t), the
number of male/female patients who also have diagnoses
x as diabetic comorbidity is Nm/f (d, x, t). The gender
ratio GR(x, t) is then related to the logarithmic quotient
of the percentage of female and male diabetes patients
who also have diagnoses x,
GR(x, t) = log

 1 +
Nf (d,x,t)
Nf (d,t)
1 + Nm(d,x,t)Nm(d,t)

 . (1)
Further, let Nm/f (t) be the number of male/female pa-
tients in age group t, and Nm/f (y, t) the number of
male/female patients having y diagnoses, or being de-
scribed y drugs, in age group t. The gender ratios for
drugs and diagnoses GR(y, t) are obtained by replac-
ing Nm/f (d, t) (Nm/f (d, x, t)) by Nm/f(t) (Nm/f (y, t))
in equation 1.
Lead/lag indicator. LetM(di, x, t) be the number
of patients diagnosed with di and x in year t. To in-
dicate the number of patients not having di and/or x,
we exchange di (x) by ¬di (¬x) respectively, for exam-
ple M(di,¬x, t) is the number of people having diabetes
but not diagnoses x in year t. The patient numbers
M(di, x, t2|di, x, t1) denote the number of patients hav-
ing diagnoses di and x in year t2 and t1. The indicator
for di leading x, Ilead(di, x), is then given by
Ilead(di, x) =
M(di, x, 2007|di,¬x, 2006)
M(di, x, 2007)
(2)
−
M(di, x, 2006|di,¬x, 2007)
M(di, x, 2006)
.
The first summand is the number of patients which had
both di and x in 2007, but only di in 2006. This is
compared to the number of patients having both di and
x in 2006, but only di in 2007. If there would be any
temporal order between having x and di, for example
that one is much more likely to be diagnosed with x if
one already has the diagnoses di, these two terms can
be expected to substantially differ. In particular, val-
ues for Ilead(di, x) > 0 suggest that di leads x. Using
the same rational, an indicator quantifying whether be-
ing diagnosed with di tends to occur after one has been
diagnosed with x can be constructed, the lag indicator
Ilag(di, x) given by
Ilag(di, x) =
M(di, x, 2007|¬di, x, 2006)
M(di, x, 2007)
(3)
−
M(di, x, 2006|¬di, x, 2007)
M(di, x, 2006)
.
Positive values of Ilag(di, x) suggest that there is a ten-
dency that the diagnoses of diabetes lags the diagnoses
of the other disease x. One may observe high values for
Ilead/lag(di, x) because the frequency of the diagnoses x
itself is very small and thus the quotients in the above
definitions become large. To compensate for this we ex-
clude diagnoses x for which M(di, x, 2007) < z for some
value z. Finally a statistical test is developed to assess
the significance of Ilead/lag(di, x) values. First, surro-
gate data is created by keeping the diagnoses for each
patient fixed, but scrambling the information about the
year when the diagnoses was made. Assume that pa-
tient a hasNa diagnoses {xi}i∈{1,...,Na} made in the years
{τi}i∈{1,...,Na} respectively. The surrogate data is con-
structed by replacing {τi}i∈{1,...,Na} by a random per-
mutation of itself and then compute the surrogate in-
dicators I˜lead/lag(di, x). This procedure is repeated 100
times. Let M˜(di, x, 2007) be the number of patients with
diagnoses di and x in the surrogate data. For each value
of Ilead/lag(di, x) we pick all surrogate indicator values
for which
∣∣∣∣∣
M˜(di, x, 2007)−M(di, x, 2007)
M˜(di, x, 2007)
∣∣∣∣∣ < 0.5 (4)
holds to avoid spurious results from potential size-
dependences on the frequencies of the diagnoses. The
p-value for Ilead/lag(di, x) is the fraction of surrogate val-
ues for which both Ilead/lag(di, x) > I˜lead/lag(di, x) and
equation 4 holds. A p-value of 0.01, for instance, indi-
cates that one percent of the relevant surrogate indicator
values are larger than the observed lead or lag indicator;
there is a chance of one percent to obtain indicator val-
ues as large as the observed ones from a patient data-set,
where all time information has been randomly shuffled.
The above method is applied to male and female patients
with Type I (using z = 3) and II (z = 20) diabetes, re-
spectively. For DM1 only patients below an age of thirty
were included in the analysis.
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FIG. 1: Values for relative risks (left panels) and gender ratios (right panels) for the 123 identified comorbidities computed
using a patient sample of all persons receiving a drug used in diabetes (ATC code A10). The results from the inpatient sample
are reproduced to large parts, only disorder M23 exhibits non-significant p-values.
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TABLE I: ICD code and disease name for the 123 comorbidities identified
in the co-occurrence analysis. For the age groups with the smallest p-
value the relative risks RR, patient ages, and the corresponding p-values
are shown for DM1 and DM2, respectively. Where the patient sample
was too small to apply the statistical tests missing values are shown.
DM1 DM2
ICD Diagnosis p RR1 age p RR2 age
A09 Diarrhoea and gastroenteritis of infectious origin 0.004 4.4 (3.0-6.3) 45-50 0.0003 1.6 (1.5-1.7) 80-85
A41 Other septicaemia < 10−4 12 (8.2-18) 45-50 < 10−4 2.7 (2.4-2.9) 65-70
A46 Erysipelas 0.0009 3.7 (2.9-4.8) 65-70 < 10−5 2.7 (2.5-3.0) 65-70
B17 Other acute viral hepatitis 0.006 7.1 (4.0-13) 50-55 0.002 6.9 (4.5-11) 40-45
B18 Chronic viral hepatitis 0.0007 6.3 (4.4-9.0) 50-55 0.0006 3.2 (2.6-3.8) 50-55
B35 Dermatophytosis 0.01 3.5 (2.4-5.2) 65-70 0.0005 2.6 (2.2-3.0) 65-70
B37 Candidiasis 0.002 5.5 (3.7-8.2) 55-60 0.002 2.1 (1.8-2.5) 65-70
B99 Other and unspecified infectious diseases 0.003 4.7 (3.3-6.9) 65-70 0.004 1.7 (1.5-2.0) 80-85
C25 Malignant neoplasm of pancreas 0.0006 8.6 (5.6-13) 55-60 0.0006 2.5 (2.1-2.8) 65-70
D50 Iron deficiency anaemia 0.0003 3.7 (3.0-4.6) 70-75 < 10−5 2.7 (2.4-2.8) 65-70
D63 Anaemia in chronic disease < 10−4 6.3 (4.9-8.2) 65-70 < 10−4 2.8 (2.5-3.2) 65-70
D64 Other anaemia < 10−5 4.9 (4.2-5.8) 65-70 < 10−6 2.6 (2.4-2.8) 65-70
D69 Purpura and other haemorrhagic conditions 0.009 3.6 (2.4-5.4) 55-60 0.001 2.0 (1.7-2.2) 65-70
E03 Other hypothyroidism 0.0001 9.3 (6.4-13) 35-40 0.0001 1.7 (1.6-1.9) 65-70
E05 Thyrotoxicosis 0.009 5.3 (3.1-8.9) 40-45 0.001 1.6 (1.5-1.8) 70-75
E06 Thyroiditis < 10−6 38 (26-57) 10-15 0.04 1.7 (1.3-2.1) 55-60
E16 Other disorders of pancreatic internal secretion < 10−15 170 (130-223) 20-25 < 10−8 5.4 (5.0-5.7) 80-85
E21 Hypoparathyroidism 0.0006 6.1 (4.4-8.6) 65-70 0.0002 3.0 (2.6-3.5) 67-70
E66 Obesity < 10−6 3.7 (3.3-4.1) 65-70 < 10−16 4.8 (4.6-5.0) 55-60
E78 Dis. of lipoprotein metabolism and other lipidaemia < 10−5 3.4 (3.0-3.7) 60-65 < 10−15 3.9 (3.7-4.0) 55-60
E79 Dis. or purine and pyrimidine metabolism < 10−4 3.2 (2.8-3.7) 65-70 < 10−7 2.5 (2.4-2.6) 65-70
E86 Volume depletion 0.0001 9.4 (6.5-14) < 10−15 0.0003 1.7 (1.6-1.8) 75-80
E87 Other dis. of fluid, electrolyte and acid-base balance < 10−4 5.9 (4.7-7.3) 60-65 < 10−5 2.5 (2.3-2.6) 65-70
E88 Other metabolic disorders 0.0001 6.4 (4.9-8.4) 60-65 < 10−7 5.1 (4.7-5.6) 60-65
F01 Vascular dementia 0.0008 3.0 (2.4-3.6) 75-80 < 10−4 2.1 (1.9-2.2) 75-80
F03 Unspecified dementia 0.001 2.5 (2.1-2.9) 75-80 < 10−4 1.8 (1.7-1.9) 75-80
F07 Pers. and behav. dis. due to known physiological cond. 0.002 3.8 (2.9-5.1) 75-80 0.001 2.4 (2.0-2.7) 65-70
F10 Use of alcohol 0.02 2.3 (1.7-3.2) 40-45 0.0007 2.1 (1.9-2.4) 45-50
F17 Use of tobacco 0.0004 3.3 (2.7-4.1) 50-55 < 10−6 2.8 (2.6-3.0) 50-55
F20 Schizophrenia 0.09 2.1 (1.2-3.7) 65-70 0.001 3.4 (2.7-4.2) 45-50
F25 Schizoaffective disorders - - - 0.003 4.3 (3.0-6.2) 40-45
F32 Depressive episode 0.001 2.3 (1.9-2.6) 65-70 < 10−4 1.7 (1.6-1.8) 65-70
F33 Recurrent depressive disorder 0.05 1.9 (1.3-2.6) 65-70 0.003 4.8 (3.3-7.0) 35-40
F79 Unspecified mental retardation - - - 0.009 9.3 (6.0-15) 40-45
G20 Parkinson’s disease 0.002 2.3 (1.9-2.7) 75-80 0.001 1.5 (1.4-1.6) 75-80
G30 Alzheimer’s disease 0.04 1.7 (1.3-2.1) 75-80 0.001 1.5 (1.4-1.7) 75-80
G40 Epilepsy 0.004 4.6 (3.1-6.9) 35-40 0.003 1.6 (1.4-1.7) 65-70
G45 Transient cerebral ischaemic attacks 0.006 2.8 (2.1-3.7) 60-65 0.0005 1.7 (1.6-1.9) 65-70
G46 Vascular syndromes of brain in cerebrovascular diseases 0.002 3.9 (3.0-5.3) 80-85 0.012 1.9 (1.6-2.3) 70-75
G47 Sleep disorders 0.02 1.9 (1.5-2.4) 60-65 0.0001 2.3 (2.1-2.6) 50-55
G62 Other polyneuropathies < 10−5 8.2 (6.6-10) 55-60 < 10−5 2.7 (2.5-3.0) 65-70
G63 Polyneuropathy in diseases c. e. < 10−10 20 (17-23) 65-70 < 10−11 8.0 (7.6-8.4) 65-70
G81 Hemiplegia 0.008 3.9 (2.6-5.3) 65-70 0.001 1.9 (1.6-2.3) 65-70
H21 Other disorders of iris and ciliary body 0.001 10 (6.2-16) 75-80 0.006 6.2 (4.0-9.4) 55-60
H25 Senile cataract < 10−4 4.7 (3.9-5.7) 55-60 0.0002 2.0 (1.8-2.2) 55-60
H26 Other cataract 0.001 5.2 (3.7-7.3) 55-60 0.004 2.3 (1.9-2.8) 55-60
H33 Retinal detachments and breaks 0.0003 18 (10-32) 30-35 0.05 2.3 (1.6-3.5) 45-50
H35 Other retinal disorders < 10−6 10 (8-12) 55-60 < 10−6 4.3 (3.9-4.7) 55-60
H36 Retinal disorders in diseases c. e. < 10−16 200 (160-250) 30-35 0.08 230 (180-310) 30-35
H40 Glaucoma 0.0002 14 (8.7-23) 40-45 0.003 1.9 (1.6-2.2) 60-65
H43 Disorders of vitreous body < 10−6 36 (25-53) 45-50 < 10−4 4.9 (4.1-5.9) 55-60
H54 Blindness and low vision 0.01 4.6 (2.7-7.8) 65-70 0.002 3.0 (2.4-3.6) 65-70
I10 Essential (primary) hypertension < 10−8 5.3 (4.8-5.9) 65-70 < 10−16 9.5 (8.8-10) 45-50
I11 Hypertensive heart disease 0.0005 3.6 (2.9-4.5) 60-65 < 10−7 2.9 (2.7-3.1) 65-70
Continued on next page
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TABLE I – continued from previous page
DM1 DM2
ICD Diagnosis p RR1 age p RR2 age
I12 Hypertensive chronic kidney disease 0.0002 20 (12-35) 45-50 0.001 3.4 (2.8-4.1) 65-70
I13 Hypertensive heart dis. and hypertensive renal dis. 0.002 7.6 (4.7-12) 65-70 0.001 5.1 (3.9-6.6) 60-65
I15 Secondary hypertension 0.01 4.8 (2.7-8.3) 55-60 0.0006 11 (7.1-18) 40-45
I20 Angina pectoris 0.0007 3.2 (2.6-3.9) 55-60 < 10−7 2.3 (2.2-2.5) 65-70
I21 Acute myocardial infarction < 10−4 3.2 (2.8-3.7) 75-80 < 10−7 2.9 (2.7-3.1) 65-70
I24 Other acute ischaemic heart diseases < 10−4 6.6 (5.2-8.3) 65-70 < 10−4 3.1 (2.8-3.4) 65-70
I25 Chronic ischaemic heart disease < 10−8 5.3 (4.7-5.9) 60-65 < 10−16 3.3 (3.2-3.4) 65-70
I27 Other pulmonary heart diseases 0.004 2.5 (2.0-3.1) 75-80 0.0002 2.4 (2.1-2.6) 65-70
I34 Nonrheumatic mitral valve disorders 0.001 2.4 (2.0-2.8) 75-80 < 10−5 2.3 (2.2-2.5) 65-70
I35 Nonrheumatic aortic valve disorders 0.004 2.7 (2.1-3.4) 65-70 < 10−4 1.8 (1.7-1.9) 75-80
I42 Cardiomyopathy < 10−4 4.0 (3.3-4.7) 65-70 < 10−8 3.0 (2.8-3.2) 65-70
I44 Atrioventricular and left bundle-branch block 0.0004 5.1 (3.9-6.8) 60-65 < 10−5 2.5 (2.3-2.7) 65-70
I45 Other conduction disorders 0.007 3.1 (2.3-4.2) 70-75 0.0007 2.1 (1.9-2.4) 70-75
I47 Paroxysmal tachycardia 0.0004 3.3 (2.7-4.0) 75-80 0.0003 2.0 (1.8-2.2) 65-70
I48 Atrial fibrillation and flutter < 10−4 2.1 (1.9-2.3) 75-80 < 10−9 2.0 (1.9-2.0) 75-80
I49 Other cardiac arrhythmias 0.008 2.2 (1.8-2.8) 70-75 0.001 1.5 (1.4-1.6) 75-80
I50 Heart failure < 10−7 5.2 (4.7-5.9) 65-70 < 10−14 3.8 (3.6-3.9) 65-70
I51 Complications & ill-defined descriptions of heart dis. 0.0002 3.4 (2.8-4.0) 75-80 < 10−6 3.1 (2.8-3.4) 65-70
I63 Cerebral Infarction 0.0002 4.4 (3.5-5.6) 60-65 < 10−6 2.6 (2.4-2.8) 65-70
I64 Stroke, not specified as haemorrhage or infarction < 10−4 4.5 (3.7-5.5) 65-70 < 10−6 2.8 (2.6-3.1) 65-70
I65 Occlusion and stenosis of precerebral arteries < 10−4 5.3 (4.4-6.4) 60-65 < 10−8 3.0 (2.8-3.1) 65-70
I67 Other cerebrovascular diseases 0.0001 5.0 (3.9-6.2) 60-65 < 10−5 2.2 (2.1-2.3) 70-75
I69 Sequelae of cerebrovascular disease 0.005 3.5 (2.5-4.9) 60-65 < 10−6 3.0 (2.8-3.3) 65-70
I70 Atherosclerosis < 10−8 6.0 (5.4-6.7) 70-75 < 10−11 3.0 (2.5-3.5) 65-70
I73 Other peripheral vascular diseases < 10−7 5.7 (5.1-6.5) 65-70 < 10−13 3.9 (3.7-4.1) 65-70
I74 Arterial embolism and thrombosis 0.002 5.4 (3.7-7.7) 60-65 0.0004 3.0 (2.5-3.5) 60-65
I77 Other disorders of arteries and arterioles 0.001 10 (6.1-17) 50-55 0.0006 2.5 (2.2-2.9) 70-75
I79 D. of arteries, arterioles and capillaries in diseases c. e. < 10−7 23 (18-29) 70-75 < 10−6 5.7 (5.2-6.1) 75-80
I85 Esophageal varices 0.005 4.3 (2.9-6.4) 55-60 0.0003 3.0 (2.5-3.5) 55-60
I87 Other disorders of veins 0.009 3.7 (2.5-5.5) 60-65 0.0004 2.3 (2.1-2.6) 65-70
J15 Bacterial pneumonia n. e. c. 0.02 2.5 (1.8-3.3) 70-75 0.0001 2.4 (2.2-2.7) 65-70
J18 Pneumonia, organism unspecified < 10−4 2.7 (2.4-3.0) 75-80 < 10−6 2.3 (2.1-2.4) 65-70
J20 Acute bronchitis 0.03 1.9 (1.5-2.6) 80-85 0.0007 2.2 (2.0-2.5) 65-70
J22 Unspecified acute lower respiratory infection 0.02 3.4 (2.1-5.6) 75-80 0.002 3.1 (2.5-3.9) 65-70
J44 Other chronic pulmonary diseases 0.0003 2.9 (2.5-3.5) 55-60 < 10−8 2.2 (2.1-2.3) 65-70
J81 Pulmonary oedema 0.0003 9.9 (6.6-15) 60-65 < 10−4 3.7 (3.2-4.3) 65-70
J90 Pleural effusion, not elsewhere classified 0.0004 3.4 (2.1-5.6) 75-80 0.0001 3.1 (2.5-3.9) 65-70
J96 Respiratory failure, n. e. c. 0.001 9.4 (5.7-16) 10-15 < 10−4 2.3 (2.1-2.5) 65-70
K29 Gastritis and duodenitis 0.01 1.8 (1.5-2.1) 60-65 0.0002 1.5 (1.4-1.5) 70-75
K40 Inguinal hernia 0.04 0.37 (0.23-0.60) 75-80 0.001 0.48 (0.41-0.56) 65-70
K52 Other & unspec. noninfective gastroenteritis and colitis 0.006 2.1 (1.7-2.6) 75-80 0.0008 1.5 (1.4-1.6) 80-85
K70 Alcoholic liver disease 0.005 4.0 (2.7-5.7) 45-50 0.0001 2.6 (2.3-2.9) 55-60
K71 Toxic liver disease 0.05 2.8 (1.6-4.9) 55-60 0.0003 14 (8.5-23) 35-40
K74 Fibrosis and cirrhosis of liver 0.0004 5.0 (3.7-6.6) 55-60 < 10−4 2.4 (2.2-2.7) 65-70
K76 Other diseases of liver 0.0005 2.7 (2.2-3.1) 60-65 < 10−8 3.0 (2.8-3.2) 55-60
K80 Cholelithiasis 0.008 1.7 (1.5-2.0) 75-80 < 10−4 1.5 (1.4-1.6) 80-85
K83 Other diseases of biliary tract 0.003 7.5 (4.6-12) 50-55 0.03 1.4 (1.2-1.6) 80-85
K85 Acute pancreatitis 0.006 4.5 (3.0-6.9) 50-55 < 10−4 4.7 (3.9-5.8) 45-50
K86 Other diseases of pancreas < 10−5 13 (9.3-17) 50-55 < 10−5 11 (8.4-14) 40-45
K90 Intestinal malabsorption 0.001 10 (6.3-17) 10-15 0.4 1.2 (0.7-2.2) 60-65
L03 Cellulitis and acute lymphangitis 0.0005 5.5 (4.0-7.4) 65-70 0.0006 2.5 (2.1-2.9) 65-70
L30 Other and unspecified dermatitis 0.01 5.1 (3.0-8.7) 45-50 0.001 1.9 (1.7-2.1) 80-85
L89 Decubitus ulcer 0.0002 7.2 (5.2-9.9) 65-70 < 10−4 2.2 (2.0-2.4) 80-85
L97 Ulcer of lower limb n. e. c. < 10−4 7.4 (5.8-9.4) 65-70 < 10−6 4.2 (3.9-4.6) 65-70
L98 Other disorders of skin and subcutaneous tissue < 10−5 9.0 (7.2-11) 70-75 < 10−4 3.4 (3.1-3.9) 65-70
M20 Acquired deformities of fingers and toes 0.09 0.44 (0.25-0.88) 60-65 0.002 0.41 (0.34-0.49) 65-70
M23 Internal derangement of knee 0.03 0.31 (0.19-0.52) 60-65 0.0006 0.45 (0.40-0.52) 65-70
M47 Spondylosis 0.04 1.7 (1.3-2.1) 85-90 0.0003 1.6 (1.5-1.7) 70-75
M54 Dorsalgia 0.06 1.3 (1.1-1.6) 65-70 0.002 1.4 (1.3-1.5) 60-65
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DM1 DM2
ICD Diagnosis p RR1 age p RR2 age
M86 Osteomyelitis < 10−6 13 (10-16) 65-70 < 10−5 4.4 (3.9-5.0) 65-70
N04 Nephrotic syndrome < 10−4 33 (19-56) 45-50 0.001 4.9 (3.8-6.4) 60-65
N08 Glomerular d. in diseases c. e. < 10−12 128 (98-166) 40-45 < 10−9 8.6 (8.2-9.1) 65-70
N17 Acute renal failure < 10−4 13 (8.9-20) 45-50 < 10−6 3.4 (3.1-3.7) 65-70
N18 Chronic renal failure < 10−10 8.0 (7.2-8.9) 65-70 < 10−14 4.2 (4.0-4.4) 65-70
N19 Unspecified renal failure < 10−7 9.4 (8.1-11) 65-70 < 10−6 3.2 (2.9-3.5) 65-70
N25 Disorders resulting from impaired renal tubular fct. 0.002 9.0 (5.5-15) 70-75 0.001 3.9 (3.1-4.9) 65-70
N28 O. d. of kidney and ureter, n. e. c. 0.004 5.8 (3.7-9.1) 50-55 0.0008 2.7 (2.3-3.2) 55-60
N39 Other disorders of urinary system < 10−4 2.5 (2.2-2.8) 80-85 < 10−7 1.8 (1.7-1.9) 80-85
N47 Disorders of prepuce 0.007 6.0 (3.5-10) 45-50 0.001 3.1 (2.5-3.8) 55-60
